<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00140790</url>
  </required_header>
  <id_info>
    <org_study_id>CVM-RCT-2005-02</org_study_id>
    <nct_id>NCT00140790</nct_id>
  </id_info>
  <brief_title>Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study</brief_title>
  <official_title>Effects of Valsartan on Cardiovascular Events in Patients With Renal Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kumamoto University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kumamoto University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if an angiotensin II receptor blocker, valsartan&#xD;
      160 mg/day is more effective to reduce the incidence of cardiovascular events as compared to&#xD;
      40 mg/day in patients with moderate renal dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is well known that patients with renal dysfunction have a poor prognosis concerning&#xD;
      cardiovascular diseases. That is called &quot;cardiorenal syndrome&quot;. It was reported that&#xD;
      valsartan was effective in reducing the urine albumin extraction rate in patients with hyper-&#xD;
      or normotension. We hypothesized that valsartan was more effective to prevent cardiovascular&#xD;
      events by the intermediary of improving renal function.&#xD;
&#xD;
      The primary endpoints are:&#xD;
&#xD;
        -  cardiovascular events (cardiac death, non-fatal myocardial infarction, unstable angina&#xD;
           requiring rehospitalization, congestive heart failure requiring rehospitalization,&#xD;
           revascularization procedures including coronary angioplasty or coronary artery bypass&#xD;
           grafting;Stroke or transient ischaemic attack, dissociation aneurysm of the aorta&#xD;
           needing hospitalisation;Lower limbs artery obstruction needing hospitalisation .&#xD;
&#xD;
        -  end-stage renal dysfunction (introduction of hemodialysis or kidney transplantation)&#xD;
&#xD;
        -  50% reduction of creatinine clearance&#xD;
&#xD;
      The secondary endpoints are:&#xD;
&#xD;
        -  systolic and diastolic function of the left ventricle estimated by echocardiography (%&#xD;
           FS and E/A ratio)&#xD;
&#xD;
        -  specific biochemical markers for cardiac or renal function (urine microalbumin, plasma&#xD;
           B-type natriuretic peptide, plasma type 1 plasminogen activator inhibitor, plasma&#xD;
           cystatin C)&#xD;
&#xD;
        -  % changes of creatinine clearance between start and end of the study period&#xD;
&#xD;
        -  transition of 1/(serum Cr) in patients whose u-prot/u-Cr is equal to or more than 1.0&#xD;
&#xD;
        -  transition of serum K&#xD;
&#xD;
        -  HbA1c&#xD;
&#xD;
        -  New onset Atrial Fibrillation&#xD;
&#xD;
        -  New onset Diabetes&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The number of actual events was extremely low. We extended the study period, but it was still&#xD;
    not enough. Also, many patients were loss of follow up.&#xD;
  </why_stopped>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>End-stage renal dysfunction</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>50% reduction of creatinine clearance</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>% FS and E/A ratio</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific biochemical markers for cardiac or renal function</measure>
    <time_frame>6 months and 1 year and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% changes of creatinine clearance</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1/(serum Cr)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum K</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>U-prot/U-Cr</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug effects</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New onset Atrial Fibrillation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1000</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Valsartan 40mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Dose valsartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 160mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High Dose valsartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valsartan</intervention_name>
    <description>valsartan 40 or 160 (80) mg per day</description>
    <arm_group_label>Valsartan 160mg</arm_group_label>
    <arm_group_label>Valsartan 40mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (all required):&#xD;
&#xD;
          -  Systolic blood pressure (SBP) &gt;/= 140 and/or diastolic blood pressure (DBP) &gt;/= 90&#xD;
             (untreated hypertension cases); or SBP&gt;/=130 and/or DBP&gt;/=80 (treated hypertension&#xD;
             cases)&#xD;
&#xD;
          -  Patients with coronary artery disease (more than 50% stenosis on coronary angiography&#xD;
             [CAG], coronary computed tomography [CT] or coronary magnetic resonance angiography&#xD;
             [MRA]; coronary spasm; or history of percutaneous coronary intervention&#xD;
             [PCI]);Unstable angina patient&#xD;
&#xD;
          -  Creatinine clearance between 30.0 and 89.9 ml/min&#xD;
&#xD;
        Exclusion Criteria (at least one of following):&#xD;
&#xD;
          -  Reduced left ventricular (LV) function (ejection fraction [EF] equal to or less than&#xD;
             40%)&#xD;
&#xD;
          -  Hyperpotassemia (serum potassium equal to or more than 5.5 mEq/l)&#xD;
&#xD;
          -  Rapid progressive glomerular nephritis&#xD;
&#xD;
          -  Nephrotic syndrome&#xD;
&#xD;
          -  Renal artery stenosis&#xD;
&#xD;
          -  Uncontrolled diabetes (HbA1c equal to or more than 9.0%)&#xD;
&#xD;
          -  History of allergy to valsartan&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hisao Ogawa, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiovascular Medicine, Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>August 31, 2005</study_first_submitted>
  <study_first_submitted_qc>August 31, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2005</study_first_posted>
  <last_update_submitted>February 25, 2016</last_update_submitted>
  <last_update_submitted_qc>February 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kumamoto University</investigator_affiliation>
    <investigator_full_name>Hisao Ogawa</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Cardiorenal syndrome</keyword>
  <keyword>Renal dysfunction</keyword>
  <keyword>Cardiovascular events</keyword>
  <keyword>Valsartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

